Government – Talk Bio

Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions

2 weeks ago talkbio0Tagged Benefit, dealmaking, direct-to-consumer sales, drug price, gene therapy, Government, Hemlibra, Investments, manager, Manufacturing, Ocrevus, Pharmaceutical Services, pipeline, R&D, Roche (company), U.S., Vabysmo

Roche; drug pricing; US government; pharmacy benefit managers; direct-to-consumer sales; pipeline; dealmaking; US investment; manufacturing; gene therapy; R&D; Ocrevus; Hemlibra; Vabysmo

US Government Backs In Vivo Cell Therapy Startup with Major Funding

4 weeks ago talkbio0Tagged Cell Therapy, federal funding, Government, in vivo, startup, U.S.

federal funding; in vivo cell therapy; startup; immunoVec; US government

Despite Government Shutdown, Companies Still Plan to Submit FDA Applications

1 month ago talkbio0Tagged AbbVie, amgen, Application procedure, biology (field), drug applications, funding lapse, Government, J&J, Myers Squibb, Pfizer, pharmaceutical delays, shutdown, United States Food and Drug Administration, user fees

FDA shutdown; new drug applications; biologic applications; user fees; pharmaceutical delays; government funding lapse; AbbVie; Amgen; Bristol Myers Squibb; J&J; Pfizer

A Concerning Pattern: Pharma Mulls UK Divestments as Government Action Lags in Life Sciences

2 months ago talkbio0Tagged AstraZeneca, Biological Science Disciplines, drug price, drug spending, eli lilly, Government, Investments, Merck, Nance-Horan syndrome, pharmaceutical divestment, Policy, R&D, sanofi, UK

UK life sciences; pharmaceutical divestment; Merck; AstraZeneca; Sanofi; Eli Lilly; R&D investment; drug pricing; government policy; NHS drug spending

Eli Lilly Pauses UK Biotech Incubator Plans Amid Concerns Over NHS Drug Pricing

2 months ago talkbio0Tagged Biological Science Disciplines, biotech incubator, biotech industry, Eli, Eli Lilly, Gateway Labs, Government, Investments, Nance-Horan syndrome, Pauses, pharmaceutical innovation, UK

Eli Lilly; Gateway Labs; UK biotech incubator; pause; investment; NHS drug spending; life sciences; biotech industry; government funding; pharmaceutical innovation

Merck Moves All R&D Operations Out of UK, Citing Unfavorable Environment

2 months ago talkbio0Tagged Biological Science Disciplines, Brexit impact, Drug Discovery, Government, Investments, layoffs, London Bioscience Innovation Centre, Merck, Multiple Sulfatase Deficiency Disease, Relocation of home or business, UK

Merck; MSD; R&D relocation; UK life sciences; drug discovery; Brexit impact; London Bioscience Innovation Centre; Francis Crick Institute; government investment; layoffs